SLC5A2 and type 2 diabetes mellitus: Improved clinical outcomes in T2DM, in terms of a reduction in CV events and renal outcomes such as albuminuria and eGFR decline, are reported with the administration of sodium–glucose cotransporter type 2 (SGLT2) inhibitors [92,93].